Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2023) 142 (10): 878–886.

https://doi.org/10.1182/blood.2022019386

Published: 2023

Includes: Supplemental data

Journal Articles

GPC-100 Is a Novel CXCR4 Inhibitor That Leads to Improved in Vitro Potency and In Vivo Efficacy in Stem Cell Mobilization When Combined with a Beta-Blocker

Juan Jose Fung, Valerie Chiou, Jaemin Lee, Yongdae Jang, Junhee Choi, Piotr Zalicki, Thomas Cayton, Ashley Chin, Niña Caculitan, SoHui Kim, Jiyeong Lee, Devki Sukhtankar, Eunhee Kim, Josephine Cardarelli

Blood (2022) 140 (Supplement 1): 4489–4490.

https://doi.org/10.1182/blood-2022-160248

Published: 2022

Journal Articles

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome

Courtnee A. Clough, Joseph Pangallo, Martina Sarchi, Janine O. Ilagan, Khrystyna North, Rochelle Bergantinos, Massiel C. Stolla, Jasmine Naru, Patrick Nugent, Eunhee Kim, Derek L. Stirewalt, Arvind R. Subramaniam, Omar Abdel-Wahab, Janis L. Abkowitz, Robert K. Bradley, Sergei Doulatov

Blood (2022) 139 (13): 2038–2049.

https://doi.org/10.1182/blood.2021012652

Published: 2022

Includes: Supplemental data

Journal Articles

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Philippe Armand, John Kuruvilla, Alex F. Herrera, Vincent Ribrag, Pauline Brice, Catherine Thieblemont, Bastian Von Tresckow, Eunhee Kim, Robert Orlowski, Samhita Chakraborty, Patricia Marinello, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3924.

https://doi.org/10.1182/blood-2021-148528

Published: 2021

Journal Articles

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Jane N. Winter, Akash Nahar, Eunhee Kim, Patricia Marinello

Blood (2021) 138 (Supplement 1): 1379.

https://doi.org/10.1182/blood-2021-147276

Published: 2021

Journal Articles

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Philippe Armand, Pier Luigi Luigi Zinzani, Hun Ju Lee, Nathalie Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2021) 138 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2021-147881

Published: 2021

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Blood (2019) 134 (14): 1144–1153.

https://doi.org/10.1182/blood.2019000324

Published: 2019

Includes: Supplemental data

Journal Articles

RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models

Yi-Jou Huang, BS, Ming Yan, PhD, Jia-Yu Chen, PhD, Liang Chen, PhD, Eunhee Kim, PhD, Takahiro Shima, MD PhD, Amanda G Davis, BS, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Xiang-Dong Fu, PhD, Omar I Abdel-Wahab, MD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2018-99-119104

Published: 2018

Journal Articles

Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling

Stanley C Lee, PhD, Khrystyna North, Chi-Chao Chen, Eunhee Kim, PhD, Sydney X. Lu, MD PhD, Michelle Ki, BSc, Ralph Garippa, PhD, Scott W Lowe, PhD, Robert K. Bradley, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 937.

https://doi.org/10.1182/blood-2018-99-111552

Published: 2018

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

RUNX1 Deficiency and SRSF2 Mutation Cooperate to Promote Myelodysplastic Syndrome Development

Yi-Jou Huang, BS, Ming Yan, PhD, Eunhee Kim, PhD, Amanda G Davis, BS, Takahiro Shima, MD PhD, Sayuri Miyauchi, DDS, PhD, Xiang-Dong Fu, PhD, Omar Abdel-Wahab, MD, Dong-Er Zhang, PhD

Blood (2017) 130 (Supplement 1): 119.

https://doi.org/10.1182/blood.V130.Suppl_1.119.119

Published: 2017

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Blood (2017) 130 (14): 1644–1648.

https://doi.org/10.1182/blood-2017-01-765107

Published: 2017

Includes: Supplemental data

Journal Articles

Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is Required for Adult and Embryonic Hematopoiesis and Has Non-Overlapping Roles with SRSF2 in Hematopoiesis

Young Rock Chung, MS, Hana Cho, Young Joon Kim, Eunhee Kim, PhD, Stanley Chun-Wei Lee, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 1478.

https://doi.org/10.1182/blood.V128.22.1478.1478

Published: 2016

Journal Articles

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Stanley Chun-Wei Lee, PhD, Khrystyna Dilai, Esther A. Obeng, MDPhD, Eunhee Kim, PhD, Jean-Baptiste Micol, MD PhD, Akihide Yoshimi, MD PhD, Christophe Willekens, MD, Daichi Inoue, Véronique Saada, PharmD, Hana Cho, Young Rock Chung, MS, James Palacino, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Peter Smith, Benjamin L. Ebert, MD PhD, Robert Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 961.

https://doi.org/10.1182/blood.V128.22.961.961

Published: 2016

Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Benjamin Heath Durham, MD BS, Eli L. Diamond, MD, Julien Haroche, MD PhD, Zhan Yao, PhD, Jing Ma, PhD, Sameer A. Parikh, MD, John Choi, Eunhee Kim, PhD, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, MD, Patrick Campbell, MD PhD, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Aminova Olga, Adriana Heguy, Paul Zappile, Joy Nakitandwe, BSc,MSc,PhD, James Dalton, BS, David W Ellison, MD, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, MD PhD, Phil Stephens, PhD, Vincent A. Miller, MD, Jeffrey Ross, Siraj Ali, Sebastien Héritier, Jean Donadieu, MD PhD, David Solit, MD, David M. Hyman, Jose Baselga, MD PhD, Filip Janku, MDPhD, Barry S. Taylor, PhD, Christopher Y. Park, MD, PhD, Ahmet Dogan, MD PhD, Zahir Amoura, Jean-Francois Emile, Raajit K. Rampal, MD, PhD, Neal Rosen, MD PhD, Tanja A. Gruber, MD PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 481.

https://doi.org/10.1182/blood.V126.23.481.481

Published: 2015

Journal Articles

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Benjamin Durham, MD PhD, Young Rock Chung, MS, Sasinya Scott, MPH, Bartlomiej Getta, MBBS,, Eunhee Kim, PhD, Alan Saven, MD, Richard M. Stone, MD, Kanti R Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Neal Rosen, MD PhD, Ross L. Levine, MD, Michael Berger, PhD, Martin S Tallman, MD, Omar Abdel-Wahab

Blood (2015) 126 (23): 449.

https://doi.org/10.1182/blood.V126.23.449.449

Published: 2015

Journal Articles

Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

Stanley Chun-Wei Lee, PhD, Heidi Dvinge, Eunhee Kim, PhD, Hana Cho, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Benjamin Durham, MD PhD, Young Joon Kim, Michael Thomas, Camille Lobry, PhD, Silvia Buonamici, PhD, Peter Smith, Robert K. Bradley, PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 4.

https://doi.org/10.1182/blood.V126.23.4.4

Published: 2015

NARROW

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

GPC-100 Is a Novel CXCR4 Inhibitor That Leads to Improved in Vitro Potency and In Vivo Efficacy in Stem Cell Mobilization When Combined with a Beta-Blocker

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models

Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

RUNX1 Deficiency and SRSF2 Mutation Cooperate to Promote Myelodysplastic Syndrome Development

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is Required for Adult and Embryonic Hematopoiesis and Has Non-Overlapping Roles with SRSF2 in Hematopoiesis

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only